The drugmaker hopes to show CagriSema leads to at least 25% weight loss, without increased side effects. Its lead in a red-hot market hinges on it.

Researchers looked at the health records of 17 million Americans with obesity and determined that between 2022 and 2023, rates of bariatric surgeries dropped by 25%, while prescriptions for weight-loss drugs more than doubled.

Over the past year, the question has been coming in from everywhere – from my patients and family members, from colleagues and passengers I chatted with on airplanes: Is Ozempic right for me? Or any of the blockbuster weight loss and diabetes drugs that recently caught the world’s attention?

As optimism for GLP-1 receptor agonists for weight loss has grown, so too has their use in children. Currently, liraglutide and semaglutide are the only two GLP-1 drugs FDA-approved to treat obesity in kids ages 12 and up.

A new weight loss drug target may help reduce appetite and burn calories without causing sickness, research suggests. The discovery could lead to a new treatment for millions of people with both obesity and type 2 diabetes who do not respond well to current treatments, according to experts.

"For healthcare providers, these findings suggest that anti-obesity medications may offer dual benefits," one doctor reports of the research.

Medically reviewed by Danielle Weiss, MD After losing extra pounds on Ozempic (semaglutide), some are finding themselves dealing with an unexpected issue, what's become known as "Ozempic breasts." This possible side effect of glucagon-like peptide 1 (GLP-1) agonist medication users like Ozempic,